Allergy Shots — Cost, Top Hospitals & Success Rates | MyMedicPlus

Allergy shots — medically termed subcutaneous immunotherapy (SCIT) — are the original and most established form of allergen immunotherapy, in use since Leonard Noon and John Freeman's seminal experiments with grass pollen desensitisation at St Mary's Hospital London in 1911. They involve regular subcutaneous injections of gradually increasing concentrations of standardised allergen extracts, progressively retraining the immune system's response to the specific allergens causing a patient's allergy.

Allergy shots work through a multi-mechanism immune tolerance induction: progressive dose escalation drives expansion of allergen-specific regulatory T cells (Tregs) that produce tolerogenic cytokines IL-10 and TGF-beta; IgE (the antibody responsible for immediate allergic reactions) production is suppressed while blocking IgG4 antibodies — which compete with IgE for allergen binding without triggering mast cell activation — increase substantially; mast cell and basophil threshold for allergen-triggered degranulation rises; eosinophil recruitment into target tissues decreases; and the Th1/Th2 immune balance shifts from Th2-dominated allergic pattern toward a more balanced regulatory response.

The SCIT programme follows two phases. During the build-up phase (3-6 months for conventional schedules, compressed to weeks or days with cluster/rush protocols), patients receive weekly injections at the allergy clinic, with each dose slightly higher than the previous one, working toward the target maintenance dose. During the maintenance phase (3-5 years), the maintenance dose is given every 4-8 weeks — often monthly. All injections are administered in the allergy clinic and patients wait 20-30 minutes afterwards for observation, as systemic reactions (though uncommon) are most likely in this window.

SCIT is considered the gold standard of allergen immunotherapy for its overall breadth of evidence across allergen types and its very high multi-allergen treatment capability (single injection can include multiple allergen mixes).

Allergic rhinitis and allergic rhino-conjunctivitis caused by aeroallergens — grass pollens, tree pollens, weed pollens (ragweed, mugwort), house dust mite, cat and dog dander, alternaria mould — represent the largest patient group receiving allergy shots, with SCIT producing significant and durable improvement in both seasonal and perennial rhinitis. Allergic asthma with confirmed IgE-mediated aeroallergen sensitisation is treated with SCIT in well-controlled asthma patients, reducing symptom burden and inhaled corticosteroid requirements.

Venom allergy (Hymenoptera venom — bee, yellow jacket, wasp, hornets) is one of the most compelling SCIT indications: patients who have experienced anaphylaxis from insect stings have a 60% risk of similar or more severe reaction on next sting, reduced to under 5% after a complete venom immunotherapy course. VIT is a life-changing treatment for severely venom-allergic individuals — enabling outdoor activities, gardening, and travel without constant life-threatening risk. Allergic contact dermatitis to specific allergens (latex allergy in healthcare workers) can be addressed with SCIT in specialised centres. Peanut and food allergies are typically addressed with oral immunotherapy (OIT) rather than SCIT, though multiple food SCIT protocols are under investigation.

Candidates for allergy shots are patients with moderate-to-severe IgE-mediated allergic disease not adequately controlled with pharmacotherapy, who have positive skin prick test or elevated specific IgE serology to clinically relevant allergens, who are able to commit to regular weekly then monthly clinic attendance for 3-5 years, and who have no contraindications. Skin prick testing (SPT) or serum specific IgE (ImmunoCAP testing) confirming sensitisation to the suspected allergen must precede treatment — SCIT to allergens the patient is not sensitised to provides no benefit and introduces unnecessary systemic reaction risk.

Contraindications include: severe uncontrolled asthma (FEV1 below 70% despite maximal therapy) — the most important safety contraindication, as bronchospasm significantly amplifies systemic reaction severity; concurrent beta-blocker therapy (relative contraindication — beta-blockers impair adrenaline efficacy during anaphylaxis management); autoimmune disease on immunosuppressive therapy; pregnancy (new courses); active systemic malignancy; and systemic mastocytosis (SCIT can be performed in specialised settings for venom allergy in mastocytosis). Children typically need to be cooperative with injections — generally from age 5 onwards.

Conventional SCIT uses weekly injections over 3-6 months during build-up, reaching the maintenance dose (typically 5-20 mcg of major allergen) before transitioning to monthly maintenance. This schedule has the most extensive safety evidence and is the standard approach for multi-allergen SCIT where the longer build-up allows careful dose adjustment.

Cluster immunotherapy compresses the build-up by giving 2-3 injections per visit (at 20-30 minute intervals) on 1-2 days per week, reaching maintenance in 4-8 weeks. It requires pre-medication with oral antihistamine before each cluster visit. Rush immunotherapy achieves maintenance in 3-5 days with multiple daily injections, predominantly used in venom allergy where rapid protection is urgently needed. Ultra-rush protocols achieve venom maintenance within hours in specialist centres for urgent clinical situations. For multi-allergen SCIT, separate injection sites are used for each allergen mix (typically right arm for one mix, left arm for another), or allergen mixes are formulated together if allergens are compatible and do not cross-react. Allergen extracts are standardised in 'biological units' (BAU, AU, IR) or micrograms of major allergen protein, enabling reproducible dosing across manufacturers.

Selecting the most appropriate Allergy Shots approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

SCIT achieves clinically meaningful symptom reduction in 70-80% of patients completing the full 3-5 year course. Meta-analyses demonstrate average 33% reduction in symptom scores and 38% reduction in rescue medication use compared to placebo across multiple allergens. Unlike pharmacotherapy, these benefits persist after completing treatment — a landmark study by Durham et al showed significant symptom reduction persisting 3 years after completing 3 years of grass pollen SCIT, demonstrating true immunological remission.

For venom immunotherapy, protection rate against systemic sting reactions exceeds 95% after completing a full VIT course. Studies show 78-85% of patients who discontinue after 5 years of VIT maintain long-term tolerance to stings for over 10 years. The cost-effectiveness of SCIT is well-established: compared to continued indefinite pharmacotherapy, SCIT becomes cost-neutral within 3-5 years and cost-saving thereafter, as post-treatment medication needs are substantially reduced. SCIT additionally prevents new sensitisations and reduces asthma development risk by 45% in children with allergic rhinitis — an important long-term health benefit beyond immediate symptom control.

Local injection site reactions — swelling, redness, and itching within 20 minutes of injection lasting up to 24 hours — occur in 20-30% of injections. Large local reactions (LLR) — swelling exceeding 5 cm diameter — occur in 5-10% and may require dose reduction at the next visit. Local reactions predict neither the occurrence nor severity of future systemic reactions and are not a reason to discontinue SCIT.

Systemic reactions affecting body areas beyond the injection site occur in 0.1-0.5% of SCIT injections overall: most are mild (rhinitis flare, urticaria, cough) managed with antihistamines and resolved within 30 minutes in the clinic. Severe anaphylaxis requiring intramuscular adrenaline occurs in approximately 1 per 1,000,000 injections — rates are higher with rush protocols and during the build-up phase than with established maintenance. Approximately 90% of systemic reactions occur within the 20-30 minute post-injection observation period — this is why the observation period is mandatory. Fatal anaphylaxis from SCIT has been reported at an estimated rate of 1 per 3-4 million injections, concentrated in patients with uncontrolled asthma who received injections despite this contraindication.

Each SCIT visit includes review of: any symptoms since last injection (rhinitis, asthma, skin reactions); current respiratory status and peak flow (for asthmatic patients); and any interval illness or increase in allergen exposure. Injections are not given to patients with acute asthma, fever, or severe ongoing allergic symptoms — the dose is held until the patient is stable.

Annual review assesses treatment efficacy using symptom diaries, visual analogue scales, quality-of-life questionnaires (RQLQ, SNOT-22), and medication use logs. The decision to continue to year 4 and year 5 versus stopping at 3 years is informed by clinical response and tolerability. Patients who complete the full course are counselled on expected long-term protection and the possibility of needing occasional pharmacotherapy during high allergen exposure periods or if symptoms re-emerge. Relapse within 1-2 years of completing SCIT suggests incomplete treatment response and may warrant a second course or transition to SLIT maintenance.

Allergy shots in the United States cost $1,500-$4,000 per year for the complete programme including allergen extract preparation, injection fees, and office visits, totalling $5,000-$18,000 over a 3-5 year course — though insurance typically covers most of this under allergy specialist visits. In the United Kingdom, NHS-funded SCIT is available for severe venom allergy and selected aeroallergen cases at specialist allergy centres; private SCIT costs £2,500-£6,000 per year.

Allergy shot programmes at specialist allergy clinics in India are substantially more affordable: $500-$1,500 per year including all injections, allergen extract preparation, and clinic visits, totalling $1,500-$6,000 for the full course. Apollo Hospitals, AIIMS, and Medanta allergy departments use WHO-standardised allergen extracts and follow EAACI immunotherapy protocols. Thailand's allergy immunotherapy programmes cost $600-$2,000 per year. For patients willing to attend an international allergy clinic for 3-6 months of build-up then maintain monthly locally, the cost savings are substantial.

Sublingual immunotherapy (SLIT) — allergen extracts or standardised tablets taken daily under the tongue — is the primary alternative to SCIT, offering equivalent or near-equivalent efficacy for house dust mite, grass pollen, and ragweed allergy (for which standardised tablets are available) with a superior safety profile allowing home administration. SLIT avoids the clinic visit burden of SCIT and anaphylaxis risk is substantially lower. It is the preferred route for patients who are unable to commit to weekly clinic visits, have needle phobia, or prefer home-based treatment.

Pharmacotherapy (intranasal corticosteroids, antihistamines, leukotriene receptor antagonists, anti-IgE biologics) provides symptomatic control without disease modification and must be continued indefinitely. For severe eosinophilic asthma with allergy, biologics (dupilumab, mepolizumab, benralizumab, omalizumab) provide excellent disease control as an alternative to immunotherapy in patients who are not SCIT candidates. Avoidance strategies (HEPA air filtration, mattress covers, pet dander reduction) reduce allergen load but rarely provide adequate symptom control as standalone treatment.